Home › Interpace Diagnostics Faces Nasdaq Delisting

Interpace Diagnostics Faces Nasdaq Delisting

Nov 30, 2016

NEW YORK (GenomeWeb) – Interpace Diagnostics' stock faces delisting from the Nasdaq due to the company's failure to maintain a minimum of $2.5 million in stockholders' equity, according to a document filed yesterday with the US Securities and Exchange Commission. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Aug
27
Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
17
Featured Webinar

Trends in Clinical NGS QC Management: Expert Insights to Ensure Quality Results for Your Lab

Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.

Sep
18
Featured Webinar

Validation and Internal QC of Clinical NGS to Support an Accredited Diagnostic Workflow

Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls. 

What's Popular?

In Molecular Diagnostics

  1. PGx Experts Encourage Greater Standardization of Tests to Improve Adoption, Patient Care

    Premium

  2. MDxHealth Hopes to Build Lead in Prostate Risk Testing With Utility Evidence for SelectMDx

    Premium

  3. China FDA Approves Novogene CDx Test for NSCLC Therapies

  4. OnSiteGene Developing Ultra-Fast qPCR System for Rapid Syndromic Testing

    Premium

  5. Genetic Technologies Announces Planned Chinese Joint Venture

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.